

COVID-19 Hematologic Assessment and Intervention Care Plan

Day	Phase I		Phase II		Phase III	
	1 to 3	4 to 7	8 to 10	11 to 20	21 to 40+	
Clinical Status	May experience some but not all symptoms - Low grade fever in 40% of cases, sore throat, headache, diarrhea, fatigue, altered taste and smell, decreased appetite	Possible continuation of fever, fatigue, muscle aches, chills, cough, mild chest pressure - or none of the above	Progressive cough, fatigue and respiratory distress, only 30% have fever, somnolence = silent hypoxia	Continued cough, progressive dyspnea and O2 requirements, renal, hepatic, cardiac, neurologic impairment, large vessel thrombosis	Patients slowly recover or expire, only 12-20% successfully weaned off mechanical ventilation	
Typical Care Plan	Consult PCP: PCR testing (25% false negatives), COVID-19 Positive Recommendations: Self-isolate, monitor fever, pulse oximetry, take Tylenol. Report to ER for progressive difficulty breathing or other symptoms		Admitted to hospital oxygen, fluid management, antibiotics	Admitted to ICU oxygen, anticoagulation, steroids, Remdesivir, mechanical ventilation, ECMO, or convalescent plasma	Recovery period	
CMOH Care Plan	Outpatient Course: PCP referral of COVID-19 positive patient to hematology: Baseline CBC, D-dimer, chem, LDH, CRP, CXR, and (procalcitonin if febrile).	Outpatient Course Day 7: Repeat labs: CBC, D-dimer, chem, LDH, CRP. Continue anticoagulation (or possible adjustment based on D-dimer, chem, and LDH or radiographic results).	Inpatient Care Plan: Begin anticoagulation therapy with LMWH or UFH (if no contraindication) at time of admission. Initiate steroid therapy at time of admission (10 day tapering course of dexamethasone). Manage inpatient coagulation.		Inpatient to Outpatient Transition: Hematology follow-up with weekly labs, monitor symptoms, communicate and collaborate with primary and specialty care teams. Manage anticoagulation for 1-4 months post discharge depending on clinical course.	
	If no contraindication, possible initiation of anticoagulation (prophylactic, intermediate, or therapeutic dosing) depending on degree of D-dimer elevation + any of the following: abnormal CXR, transaminitis, or rising creatinine.	Possible initiation of steroids (7-10 day course) for rising CRP, progressive respiratory symptoms, transaminitis, rising creatinine.	Outpatient Care Plan (no admission): Continue anticoagulation and repeat labs on day 14 and 21. Discontinue steroids. Consider switching to oral anticoagulants on day 14 or 21 depending on clinical course.		Manage anticoagulation for 1-4 months depending on clinical course.	